Current pharmaceutical design最新文献

{"title":"Cancer Drug Targeting: Molecular Mechanism, Approaches, and Regulatory Framework.","authors":"Rushikesh Somnath Chandel, Hitesh Kumar Dewangan","doi":"10.2174/0113816128364722250126172914","DOIUrl":"https://doi.org/10.2174/0113816128364722250126172914","url":null,"abstract":"<p><p>Novel vaccine formulations called nano vaccines which use nanoparticles (NPs) as adjuvants or carriers, are being developed in place of conventional vaccines. The field of study on peptide-based nano vaccines is enlarging fast as a result of combining antigenic peptides with nano-transport systems. This paper explores advancements in anticancer nano vaccines, focusing on their mechanisms, challenges, and opportunities. It discusses peptide nano vaccines, personalized vaccines, cancer prevention strategies, clinical translation, and self-assembling multivalent nanovaccines. It also discusses nanocarriers' role in delivering tumorassociated antigens and immune-stimulatory adjuvants. In 2024, the American Cancer Society projects over 2 million new cancer cases in the United States, marking the first year this milestone has been surpassed. This equates to approximately 5,480 new cancer diagnoses daily. Additionally, over 611,000 cancer-related deaths are expected, which translates to more than 1,600 deaths per day. The National Centre for Health Statistics mentions the mortality data also shows the various types of cancer percentages. This guideline provides comprehensive recommendations for sponsors submitting a novel drug under Investigation use of curative cancer vaccinations, focusing on safety, effectiveness, dosage optimization, adjuvant use, patient group selection, immune response monitoring, biomarker evaluation, multi-antigen vaccine development, phase-specific difficulties, non-clinical testing, and legal frameworks, while also referencing relevant legal foundations and recommendations.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systems Pharmacology-based Drug Discovery and Active Mechanism of Ganoderma lucidum Triterpenoids for Type 2 Diabetes Mellitus by Integrating Network Pharmacology and Molecular Docking.","authors":"Junkai Shi, Jialiang Chen, Chitong Cheng, Wei Li, Ming Li, Shuhong Ye, Zhaofang Liu, Yan Ding","doi":"10.2174/0113816128365423250126035306","DOIUrl":"https://doi.org/10.2174/0113816128365423250126035306","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease primarily characterized by insufficient insulin secretion or reduced insulin sensitivity in the body's cells, leading to persistently high blood glucose levels. Ganoderma lucidum triterpenoids, as important secondary metabolites of Ganoderma lucidum, have shown preliminary potential efficacy in the treatment of T2DM according to existing research. However, due to the structural complexity and diversity of these triterpenoid compounds, as well as the intricate interactions between their therapeutic targets and active ingredients, the precise molecular and pharmacological mechanisms remain to be further explored.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;In the present research, we aim to fully employ the integrated approach of network pharmacology and molecular docking methodologies, delving deeply into the potential therapeutic targets and their underlying pharmacological mechanisms in the management of T2DM via Ganoderma lucidum triterpenoids.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The active compounds were sourced from prior research and the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Their potential targets were predicted with the aid of Swiss Target Prediction. Genes linked to T2DM were gathered from DisGeNET and GeneCards. Using Cytoscape, we established the network connecting active ingredients, targets, and pathways, and the target protein-protein interaction (PPI) network was created using data from the STRING database. The core targets of Ganoderma lucidum triterpenoids underwent gene enrichment analysis via DAVID. Lastly, to validate our chosen Ganoderma lucidum triterpenoids, we conducted molecular docking experiments between the compounds and their targets.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 53 Ganoderma lucidum triterpenoids and 116 associated targets were identified. Among these, SRC, MAPK1, MAPK3, HSP90AA1, TP53, PIK3CA, and AKT1 emerged as pivotal targets. We retrieved 447 Gene Ontology (GO) functional annotations and 153 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, notably including the PI3K-Akt signaling pathway, Endocrine resistance, Rap1 signaling pathway, and Lipid and Atherosclerosis, which are known to be associated with T2DM. Our findings suggest that Ganoderma lucidum triterpenoids may confer resistance to T2DM through mechanisms related to hyperexcitability, cell death, cell survival, proliferation, differentiation, and inflammation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;A comprehensive, interdisciplinary, and multi-technology approach has been established, which uncovers the collaborative effects and underlying principles of Ganoderma lucidum triterpenoids in the management and therapy of T2DM from a holistic perspective. This approach provides new insights into the development of novel biological control products for Type 2 Diabetes Mellitus (T2DM) and lays the foundation for future systematic studie","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eprosartan Reduces Inflammation and Oxidative Stress in Ethanol-induced Hepatotoxicity.","authors":"Ali Taheri Mirghaed, Mahboubeh Mansourian, Soroor Abdzadeh, Mahdokht Azizi, Farzaneh Karimi, Hamid Behrouj, Gholamreza Daryabor, Rozina Abbasi Larki, Sadrollah Mehrabi, Mohammad Bagher Jahantab, Amir Hossein Doustimotlagh","doi":"10.2174/0113816128342059250122060526","DOIUrl":"https://doi.org/10.2174/0113816128342059250122060526","url":null,"abstract":"<p><strong>Introduction: </strong>Eprosartan is an effective blood pressure medication that blocks the Angiotensin Type 1 (AT1) receptor. The studies conducted on Eprosartan showed anti-oxidative stress effects and modulating inflammatory mechanisms. The current research is designed to clarify and examine the possible advantageous impacts of Eprosartan against chronic ethanol-induced hepatic damage.</p><p><strong>Method: </strong>Twenty-four male Sprague-Dawley rats were haphazardly separated into four groups. The control group received normal saline 1 g/kg for 35 days (group 1). The EtOH group received 7 g/kg of 40% ethanol orally for 35 days (group 2). The EtOH+ EP group was pretreated with 60 mg/kg of Eprosartan dissolved in normal saline orally and, after 60 minutes, received 7 g/kg of 40% ethanol orally for 35 days (group 3). The EP group received only Eprosartan 60 mg/kg dissolved in normal saline for 35 days (group 4). The levels of biochemical parameters, oxidative stress markers, pro-inflammatory cytokines, and histopathological staining were evaluated in serum and liver tissue. The interactive behavior of Eprosartan with Tumor Necrosis Factor-α (TNF-α) protein was also explained by molecular docking.</p><p><strong>Results: </strong>Pre-treatment with Eprosartan (60 mg/kg) notably diminished the elevation in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT) enzymes, total triglyceride, cholesterol, total bilirubin, and inflammatory cytokines including TNF-α, Interleukin-1β (IL-1β) and Interleukin-6 (IL-6) levels, which were induced by alcohol administration (P-value ≤ 0.05). In the Eprosartan pre-treated group, malondialdehyde and protein carbonyl content of liver tissue were remarkably diminished, as compared to the ethanol-induced rats. In addition, histopathological results approved the indicated finding. Molecular docking research gives insights into potential interactions of Eprosartan with TNF-α protein.</p><p><strong>Conclusion: </strong>Our results revealed that the pre-treatment with Eprosartan (60 mg/kg) preserves against chronic alcohol-induced hepatic damage.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Difficulties in Using Natural Herbal Substances and their Current use in Some Pharmaceutical Dosage Forms.","authors":"Ece Özcan Bülbül, Neslihan Üstündağ Okur","doi":"10.2174/0113816128346715250120074519","DOIUrl":"https://doi.org/10.2174/0113816128346715250120074519","url":null,"abstract":"<p><strong>Aim: </strong>Random use of natural herbal products affects the treatment of diseases. In this review, the limitations that may be encountered in using natural substances of plant origin and the studies on using these substances in treating cancer, cognitive disorders, heart diseases, diabetes, and microbial diseases are examined and summarized.</p><p><strong>Background: </strong>People worldwide use herbal products derived from natural plants to solve health problems. It is known that random use of herbal products can negatively affect the treatment. However, people need help with the formulation or use of natural substances. There is no new disease-modifying herbal therapy available to treat diseases such as cancer, microbial disorders, diabetes, cognitive disorders, and cardiac disorders.</p><p><strong>Objective: </strong>This review aims to report the difficulties encountered in formulating and using natural herbal substances and highlight their possible use in some diseases.</p><p><strong>Materials and methods: </strong>Available information about the study was collected through many search engines such as Science Direct, PubMed, and Google Scholar.</p><p><strong>Results: </strong>Working with natural herbal substances worldwide presents many difficulties, especially a lack of knowledge, modern technological devices, or clinical studies. According to currently available studies, some natural herbal substances are effective against cancer, microbial disorders, diabetes, cognitive disorders, and heart disorders.</p><p><strong>Conclusion: </strong>Deepening the studies would be beneficial to eliminate the difficulties related to natural herbal medicines and making them more reliable. More research is needed to include these substances in the protocol and use them in treating diseases.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetics Modulators as Therapeutics for Neurological Disorders.","authors":"Mansi Gaba, Ashwani Sharma, Nitin Chitranshi, Girish Kumar, Reshu Virmani, Tarun Virmani, Dalapathi Gugulothu","doi":"10.2174/0113816128330087241030093112","DOIUrl":"https://doi.org/10.2174/0113816128330087241030093112","url":null,"abstract":"<p><p>Epigenetics mechanisms play a crucial role in regulating gene expression and cellular function in the development and progression of neurological disorders. Emerging evidence suggests that dysregulation of these epigenetic processes contributes significantly to the pathogenesis of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNAs, significantly impact neural plasticity. The use of epigenetic modulators, including DNA methyltransferase and histone deacetylase inhibitors, offers a promising strategy to correct and modify aberrant epigenetic marks, potentially restoring neurological homeostasis. This review highlights recent research findings from ongoing clinical trials and the potential benefits and challenges of epigenetic therapies for neurological disorders. We discuss the capacity of these interventions to potentially halt or reverse disease progression, their targeted nature, and their neuroprotective effects. Additionally, we address the hurdles facing the field, including issues of specificity, delivery, and long-term efficacy.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Cationic Nanoemulsions for Drug Delivery: Preparation, Properties, and Applications.","authors":"Huanfan He, Jiayu Li, Hong Meng, Yifan He, Xiaojing Pei, Ze Zhang","doi":"10.2174/0113816128357859250121120216","DOIUrl":"https://doi.org/10.2174/0113816128357859250121120216","url":null,"abstract":"<p><p>Nanoemulsions have gained popularity as drug delivery vehicles owing to the enhanced solubility of insoluble drugs, the augmented stability of photo- and thermosensitive substances, and the facilitation of transdermal permeation of efficacy substances. As the cell surfaces of the skin, cornea, gastrointestinal mucosa, and other cells in living organisms carry negative charges, cationic nanoemulsions (CNE) mainly promote drug absorption through electrostatic effects. In this review, a brief characterization of CNEs is provided, and the types of cationic agents and their roles in nanoemulsions, including cationic surfactants, cationic lipids, cationic polymers, cationized polysaccharides, and phytosphingosine (PS), are discussed. In addition, the current application circumstances of CNEs in ocular drug delivery, mucosal drug delivery, and transdermal drug delivery systems are elaborated on, and the crucial matters that require attention during the research process are briefly discussed. Eventually, the extensive application prospects of CNEs are envisioned.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Machine Learning Models for Healthcare Applications: A Precise and Patient-Centric Approach.","authors":"Bhumika Parashar, Sathvik Belagodu Sridhar, Kalpana, Rishabha Malviya, Bhupendra G Prajapati, Prerna Uniyal","doi":"10.2174/0113816128353371250119121315","DOIUrl":"https://doi.org/10.2174/0113816128353371250119121315","url":null,"abstract":"<p><strong>Background: </strong>Healthcare is rapidly leveraging machine learning to enhance patient care, streamline operations, and address complex medical issues. Though ethical issues, model efficiency, and algorithmic bias exist, the COVID-19 pandemic highlighted its usefulness in disease outbreak prediction and treatment optimization.</p><p><strong>Aim: </strong>This article aims to discuss machine learning applications, benefits, and the ethical and practical challenges in healthcare.</p><p><strong>Discussion: </strong>Machine learning assists in diagnosis, patient monitoring, and epidemic prediction but faces challenges like algorithmic bias and data quality. Overcoming these requires high-quality data, impartial algorithms, and model monitoring.</p><p><strong>Conclusion: </strong>Machine learning might revolutionize healthcare by making it more efficient and better for patients. Full acceptance and the advancement of technologies to improve health outcomes on a global scale depend on resolving ethical, practical, and technological concerns.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Effects and Mechanisms of Icaritin in Parkinson's Disease.","authors":"Chongbo Zheng, Lizhen Wu, Liang Luo, Jiating Cai, Zhihua Huang, Keqiang Tian","doi":"10.2174/0113816128344629250115074105","DOIUrl":"https://doi.org/10.2174/0113816128344629250115074105","url":null,"abstract":"<p><p>Parkinson's Disease (PD) is a neurodegenerative disorder of the central nervous system (CNS). Given the increasing age of the general population, PD has emerged as a significant public health and societal concern, impacting both individual well-being and socioeconomic progress. The present interventions have proven insufficient in impeding the progressive nature of PD. Consequently, it is imperative to promptly identify efficacious strategies for the prevention and treatment of PD. Icaritin (ICT) is a flavonoid extracted from Epimedium Brevicornu Maxim that is a phytoestrogen with antitumour, anti-inflammatory, antioxidant, antiaging, and neuroprotective properties. This paper reviews the protective effect of ICT on dopaminergic neurons through anti-oxidative stress, improving mitochondrial function, inhibiting neuroinflammatory responses, reducing Lewy body formation, and decreasing apoptosis. The primary objective of this article is to provide valuable insights and serve as a reference for the potential use of ICT in the prevention and treatment of PD.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.","authors":"Phool Chandra, Manav Ruhela, Prashant Kumar, Mayur Porwal, Anurag Verma, Himanshu Sharma, Neetu Sachan","doi":"10.2174/0113816128347722250109042022","DOIUrl":"https://doi.org/10.2174/0113816128347722250109042022","url":null,"abstract":"<p><p>Nanotechnology has emerged as a promising avenue for targeted drug delivery to the small intestine, offering precise control over drug release and enhanced therapeutic efficacy. This review discusses recent advancements and challenges in nanotechnology-based approaches for targeted drug delivery to the small intestine. The small intestine presents unique challenges for drug delivery, including enzymatic degradation, low permeability, and rapid transit time. Nanotechnology offers solutions to these challenges by providing carriers capable of protecting drugs from degradation, enhancing their absorption, and facilitating site-specific delivery. Various nanocarrier systems have been explored for targeted drug delivery to the small intestine, including liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles. These carriers can be functionalized with ligands targeting specific receptors or transporters expressed on the intestinal epithelium, enabling efficient uptake and intracellular delivery of drugs. Additionally, nanotechnology enables the controlled release of drugs, allowing for sustained and/or triggered release profiles tailored to the physiological conditions of the small intestine. This precise control over drug release can improve therapeutic outcomes while minimizing systemic side effects. Despite the significant progress in nanotechnology-based drug delivery to the small intestine, several challenges remain. These include achieving sufficient drug loading capacity, ensuring biocompatibility and safety of nanocarriers, and addressing regulatory concerns associated with their clinical translation. In conclusion, nanotechnology holds immense potential for targeted drug delivery to the small intestine, offering solutions to overcome the limitations of conventional drug delivery systems. Addressing the remaining challenges will be crucial for realizing the full therapeutic benefits of nanotechnology in treating diseases affecting the small intestine.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Emerging Prospective of Antipsychotics for Treating Neurodegenerative Disorders.","authors":"Bhavna Kumar, Arpita Sahoo, Manmohan Singhal, Garima Varshney, Tripti Haldar, Vikas Bali","doi":"10.2174/0113816128344910241211112452","DOIUrl":"https://doi.org/10.2174/0113816128344910241211112452","url":null,"abstract":"<p><p>CNS illnesses specified by slow deprivation of especially preganglionic neurons, as opposed to the selective static neuronal loss caused by a toxic or metabolic condition, are known as Neurodegenerative disorders. Neurodegenerative disorders are differentiated clinically by behavioral or cognitive problems. The management and treatment of neurodegenerative disorders pose significant challenges, necessitating a multidimensional approach. While primarily designed for psychiatric conditions, antipsychotics have shown potential in ameliorating behavioral and psychological symptoms in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. This review explores the existing literature, highlighting the potential benefits, risks, and considerations associated with incorporating antipsychotics into the treatment paradigm for neurodegenerative disorders. Additionally, it discusses the evolving landscape of personalized treatment strategies, emphasizing the need for a multidisciplinary approach to optimize patient outcomes in the complex realm of neurodegenerative disorder management.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}